---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Heterogeneity of treatment effect"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Heterogeneity of treatment effect. Topics: Lesion location: foveal and non-foveal subgroups, stratified combined analysis (topline data); Lesion location: final data with nominal p values within each subgroup; Subfoveal retinal pigment epithelium lesions: post hoc analysis; Baseline low-luminance visual deficit: healthier and less healthy retina, stratified combined analysis (topline data); 2 further topics. 6 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description/heterogeneity-of-treatment-effect"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Heterogeneity of treatment effect

<a id="heading-2.2.2.3"></a>

## 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

### Lesion location: foveal and non-foveal subgroups, stratified combined analysis (topline data)

> “The study enrolled a total of 270 patients, stratified by GA lesion size, location and choroidal neovascularization (CNV) in the fellow eye at the time of enrollment.”
> “When assessing the BCVA treatment effect by lesion location, the combined analysis, stratified by foveal and non-foveal patients, demonstrated an overall statistically significant difference between ANX007 and sham:”
> “In this study, loss was defined as loss of 15 BCVA letters or more on two consecutive visits, or a loss at the end of the 12-month treatment period.”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

| Lesion location | Sham | Vonaprument every month | Vonaprument every other month | Vonaprument pooled |
| --- | --- | --- | --- | --- |
| Foveal | “25.0%” “(11/44)” | “5.9%” “(3/51)” | “18.4%” “(9/49)” | “12.0%” “(12/100)” |
| Non-foveal | “17.8%” “(8/45)” | “5.3%” “(2/38)” | “2.3%” “(1/43)” | “3.7%” “(3/81)” |
| Stratified p value versus sham | “--” | “0.0019” | “0.0439” | “0.0015” |

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

<a id="topic-2.2.2.3-2"></a>

### Lesion location: final data with nominal p values within each subgroup

> “Eyes treated with vonaprument lost meaningfully less vision through 12 months compared to sham in 15-letter loss assessments of BCVA irrespective of lesion location”
> “Treatment effect, dose response, and statistical results were generally consistent with outcomes for the overall population in ARCHER”
> “Nominal p-value from a Chi-square test population in relevant lesion location subpopulation; Final data”
> “Nominal p-value from a Cochran-Mantel-Haenszel test (General Association) in overall population; Final data”

Source: [Goren Fein et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/05/J-Goren-Fein-RWC-Poster-FINAL-11May26.pdf)

| Lesion location | Sham | Vonaprument every other month | Vonaprument every month |
| --- | --- | --- | --- |
| Foveal, participants with loss | “25.0%” “11/44” | “16.3%” “8/49” | “5.9%” “3/51” |
| Foveal, nominal p value versus sham | “---” | “.3003” | “.0088” |
| Non-foveal, participants with loss | “17.8%” “8/45” | “2.3%” “1/43” | “5.3%” “2/38” |
| Non-foveal, nominal p value versus sham | “---” | “.0168” | “.0810” |

Source: [Goren Fein et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/05/J-Goren-Fein-RWC-Poster-FINAL-11May26.pdf)

<a id="topic-2.2.2.3-3"></a>

### Subfoveal retinal pigment epithelium lesions: post hoc analysis

> “Vision Outcomes in Eyes with Subfoveal RPE Lesions in Geographic Atrophy: A Post Hoc Analysis of the Phase 2 ARCHER Trial”
> “Historically, GA with subfoveal involved lesions was considered too advanced to show a meaningful treatment benefit”
> “76% Risk Reduction Vonaprument EM”
> “HR (CI) = 0.242 (0.067 to 0.881); Nominal p = .0204*”
> “41% Risk Reduction Vonaprument EOM”
> “HR (CI) = 0.504 (0.225 to 1.555); Nominal p = .2784”
> “Vision protection in the subfoveal population was shown across several key visual acuity measures, including:”

Source: [Barakat (2026)](https://annexonbio.com/wp-content/uploads/2026/09/913_Friday_Barakat_-Vision-Outcomes-in-Eyes-With-Subfoveal-RPE-Lesions-in-Geographic-Atrophy-A-Post-Hoc-Analysis-of-the-Phase-2-ARCHER-Trial-FINAL-25Sept26.pdf)

<a id="topic-2.2.2.3-4"></a>

### Baseline low-luminance visual deficit: healthier and less healthy retina, stratified combined analysis (topline data)

> “When assessing the BCVA treatment effect by retinal health, the combined analysis, stratified by healthier and less healthy retina, demonstrated an overall statistically significant difference between ANX007 and sham.”
> “This effect supports the potential use as an early treatment for GA:”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

| Baseline LLVD | Sham | Vonaprument every month | Vonaprument every other month | Vonaprument pooled |
| --- | --- | --- | --- | --- |
| Below 30 (healthier) | “16.9%” “(10/59)” | “0.0%” “(0/56)” | “6.3%” “(3/48)” | “2.9%” “(3/104)” |
| 30 or higher (less healthy) | “30.8%” “(8/26)” | “16.1%” “(5/31)” | “16.3%” “(7/43)” | “16.2%” “(12/74)” |
| Stratified p value versus sham | “--” | “0.0016” | “0.029” | “0.0009” |

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

<a id="topic-2.2.2.3-5"></a>

### Less advanced disease: low-luminance deficit, lesion size, and ellipsoid zone integrity (additional analyses)

> “Additional analyses were conducted to evaluate the effect of ANX007 on these measures in participants with relatively less advanced disease at baseline (less EZ loss and lower low luminance visual deficit [LLVD]).”

Source: [Vakharia (2025)](https://annexonbio.com/wp-content/uploads/2025/05/Vakharia-RWC-2025-NNT.pdf)

> “Lower low luminance visual deficit = more robust ANX007 response”
> “Smaller lesions = more robust ANX007 response”
> “More EZ remaining = more pronounced ANX007 response”
> “ANX007 has even greater effect in eyes with less advanced disease – lower LLVD, smaller GA lesions, more intact EZ”

Source: [Stanga et al. (2024)](https://annexonbio.com/wp-content/uploads/2024/12/Stanga-FloRetina-Final-Dec24.pdf)

<a id="topic-2.2.2.3-6"></a>

### Baseline characteristics associated with confirmed loss of 15 or more letters

> “BCVA ≥15-letter loss did not occur in participants with baseline BCVA <44 letters”
> “BCVA ≥15-letter loss less frequent in participants with baseline BCVA >69 letters”
> “Confirmed loss of 15 or more BCVA letters was associated with:”
> “Baseline visual acuity (BCVA) above 45 letters (20/100)”
> “All lesion types – more strongly associated in those with subfoveal lesions”

Source: [Chang (2026)](https://annexonbio.com/wp-content/uploads/2026/07/MChang-ASRS-Presentation-FINAL-18Jul26.pptx.pdf)

> “Individuals with baseline BCVA <45 letters not enrolled in ARCHER II due to very low incidence of BCVA 15-letter loss in ARCHER”
> “Enrolled patients at risk for vision loss but with enough vision to protect”

Source: [Annexon Biosciences investor event presentation (2026)](https://ir.annexonbio.com/static-files/e55e4d2a-22d8-43a8-bf8c-6449df3a261b)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
